Artikel
Primary Sjögren syndrome is often associated with other autoimmune diseases
Suche in Medline nach
Autoren
-
Antoine Murray
- Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie, Hannover; MVZ Hochsauerland, Rheumatologie, Arnsberg
-
Anna Charlotte Müller-Vahl
- Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie, Hannover
-
Nadine Zehrfeld
- Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie, Hannover
-
Franziska Maria Tapken
- Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie, Hannover
-
Sabrina Benz
- Fakultät der Sozialwissenschaften, Mannheim
-
Thomas Skripuletz
- Medizinische Hochschule Hannover, Klinik für Neurologie, Hannover
-
Torsten Witte
- Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie, Hannover
-
Tabea Seeliger
- Medizinische Hochschule Hannover, Klinik für Neurologie, Hannover
-
Diana Ernst
- Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie, Hannover
| Veröffentlicht: | 18. September 2024 |
|---|
Gliederung
Text
Introduction: Primary Sjögren syndrome (pSS) is a chronic inflammatory autoimmune disease. Whilst the disease usually affects the lachrymal and salivary glands, manifestations of other organ systems can also occur. While an association between pSS and autoimmune thyroiditis has already been established, very few publications exist regarding the association of other autoimmune diseases and pSS.
This study analyses the prevalence of other coexisting autoimmune diseases and their association with pSS disease activity or antibody status.
Methods: A retrospective assessment of 317/625 patients from the Hannover cohort with confirmed pSS diagnosis was performed. Data were collected from hospital medical records and analysed for evidence of other autoimmune diseases (Figure 1 [Fig. 1]).
Results: 112/317 (35.4%) of pSS patients had one or more additional autoimmune disease. The most frequent coexisting autoimmune disease remained autoimmune thyroiditis, occurring in 57/317 (18%) patients. Although no clear epidemiological data for autoimmune thyroiditis in the general population in Germany exist, countries sharing similar demographics have been assessed with a prevalence of 1.7–8.5% [1], [2]. Other autoimmune diseases such as chronic inflammatory demyelinating polyneuropathy [3] (CIDP) 33/317 (10.4%) and multiple sclerosis [4] (MS) 15/317 (4.7%) occurred more frequently in our pSS cohort than in countries sharing similar demographics (CIDP) and the general German population (MS). The prevalence of all analysed autoimmune diseases in our patient cohort is summarised in Figure 1 [Fig. 1]. No significant correlations were seen between additional autoimmune diseases and ESSDAI, ESSPRI or antibody status.
Conclusion: Coexisting autoimmune diseases are common in patients with primary Sjögren syndrome and some autoimmune diseases have a higher prevalence in pSS patients compared to the general population.
Disclosures: Antoine Murray: recieved travel grants from Abbvie, Novartis, Lilly, Galapagos, Pfizer and has participated in advisory boards for Abbvie und UCB.
Anna Charlotte Müller-Vahl: None declared.
Nadine Zehrfeld: received research grants by Novartis and financial support for conference attendance by Abbvie.
Franziska Tapken: None declared.
References
- 1.
- McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012 Oct;42(2):252-65. DOI: 10.1007/s12020-012-9703-2
- 2.
- Wémeau JL, Klein M, Sadoul JL, Briet C, Vélayoudom-Céphise FL. Graves' disease: Introduction, epidemiology, endogenous and environmental pathogenic factors. Ann Endocrinol (Paris). 2018 Dec;79(6):599-607. DOI: 10.1016/j.ando.2018.09.002
- 3.
- Broers MC, Bunschoten C, Nieboer D, Lingsma HF, Jacobs BC. Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2019;52(3-4):161-72. DOI: 10.1159/000494291
- 4.
- Korsukewitz C, Mäurer M, Wiendl H. MS-Versorgung heute und Vision für die Zukunft - eine Rolle für die ASV? NeuroTransmitter. 2022;33(12):32–7. DOI: 10.1007/s15016-022-2998-1
